Cargando…
The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study
Introduction Coronavirus disease 2019 (COVID-19) is a serious concern of the new era. Along with antiviral synthetic medications, there is a need to discover efficacious herbal antiviral medicines with minimum side effects in patients against COVID-19. This study aimed to assess the efficacy and saf...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085312/ https://www.ncbi.nlm.nih.gov/pubmed/37051002 http://dx.doi.org/10.7759/cureus.35881 |
_version_ | 1785021912699633664 |
---|---|
author | Abhyankar, Mahesh Kadam, Dilip Reddy, P. Raghavendra Siddiqui, Mohammed Zaki Ratheesh, M Jagmag, Tariq Tilwani, Jayesh |
author_facet | Abhyankar, Mahesh Kadam, Dilip Reddy, P. Raghavendra Siddiqui, Mohammed Zaki Ratheesh, M Jagmag, Tariq Tilwani, Jayesh |
author_sort | Abhyankar, Mahesh |
collection | PubMed |
description | Introduction Coronavirus disease 2019 (COVID-19) is a serious concern of the new era. Along with antiviral synthetic medications, there is a need to discover efficacious herbal antiviral medicines with minimum side effects in patients against COVID-19. This study aimed to assess the efficacy and safety of Imusil® among patients with mild COVID-19. Methods A prospective, randomized, multicenter, open-label, interventional study was conducted in patients with mild COVID-19 infection. Patients received either Imusil one tablet four times a day (seven days) along with the standard of care (SoC) or only SoC. The study endpoints were reverse transcription-polymerase chain reaction (RT-PCR) negativity, changes in cycle threshold (CT), clinical improvement, change in blood inflammatory indexes, and safety assessment. Results A total of 100 patients were enrolled, and 98 received at least one dose of treatment. The median age of patients was 36.0 years, and 58 were males. By day 4, 85.4% of patients in the Imusil+SoC group tested negative for RT-PCR compared to 64% of patients exhibiting the same outcome in the SoC group (P=0.0156). After eight days, clinical improvement was observed in all patients from the Imusil+SoC group, while in the SoC group, clinical improvement was observed in 94.0% of patients (P=0.4947). During follow-up visits, the average C-reactive protein (CRP) levels decreased from baseline in both treatment groups. The decrease in the levels of CRP (-7.3 mg/dL versus -5.5 mg/dL), D-dimer (-231.0 ng/mL versus -151.6 ng/mL), and interleukin 6 (IL-6) (-2.3 pg/mL versus -2.0 pg/mL) at eight days was comparatively higher in the Imusil+SoC group versus the SoC group. There were no serious treatment-emergent adverse events in the drug arm. Conclusion Imusil provides effective antiviral activity and safety in mild COVID-19 patients. Imusil ensures faster RT-PCR negativity and clinical improvement and ensures effective reduction of inflammatory markers such as CRP, D-dimer and interleukin 6. |
format | Online Article Text |
id | pubmed-10085312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-100853122023-04-11 The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study Abhyankar, Mahesh Kadam, Dilip Reddy, P. Raghavendra Siddiqui, Mohammed Zaki Ratheesh, M Jagmag, Tariq Tilwani, Jayesh Cureus Internal Medicine Introduction Coronavirus disease 2019 (COVID-19) is a serious concern of the new era. Along with antiviral synthetic medications, there is a need to discover efficacious herbal antiviral medicines with minimum side effects in patients against COVID-19. This study aimed to assess the efficacy and safety of Imusil® among patients with mild COVID-19. Methods A prospective, randomized, multicenter, open-label, interventional study was conducted in patients with mild COVID-19 infection. Patients received either Imusil one tablet four times a day (seven days) along with the standard of care (SoC) or only SoC. The study endpoints were reverse transcription-polymerase chain reaction (RT-PCR) negativity, changes in cycle threshold (CT), clinical improvement, change in blood inflammatory indexes, and safety assessment. Results A total of 100 patients were enrolled, and 98 received at least one dose of treatment. The median age of patients was 36.0 years, and 58 were males. By day 4, 85.4% of patients in the Imusil+SoC group tested negative for RT-PCR compared to 64% of patients exhibiting the same outcome in the SoC group (P=0.0156). After eight days, clinical improvement was observed in all patients from the Imusil+SoC group, while in the SoC group, clinical improvement was observed in 94.0% of patients (P=0.4947). During follow-up visits, the average C-reactive protein (CRP) levels decreased from baseline in both treatment groups. The decrease in the levels of CRP (-7.3 mg/dL versus -5.5 mg/dL), D-dimer (-231.0 ng/mL versus -151.6 ng/mL), and interleukin 6 (IL-6) (-2.3 pg/mL versus -2.0 pg/mL) at eight days was comparatively higher in the Imusil+SoC group versus the SoC group. There were no serious treatment-emergent adverse events in the drug arm. Conclusion Imusil provides effective antiviral activity and safety in mild COVID-19 patients. Imusil ensures faster RT-PCR negativity and clinical improvement and ensures effective reduction of inflammatory markers such as CRP, D-dimer and interleukin 6. Cureus 2023-03-07 /pmc/articles/PMC10085312/ /pubmed/37051002 http://dx.doi.org/10.7759/cureus.35881 Text en Copyright © 2023, Abhyankar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Abhyankar, Mahesh Kadam, Dilip Reddy, P. Raghavendra Siddiqui, Mohammed Zaki Ratheesh, M Jagmag, Tariq Tilwani, Jayesh The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study |
title | The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study |
title_full | The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study |
title_fullStr | The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study |
title_full_unstemmed | The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study |
title_short | The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study |
title_sort | efficacy and safety of imusil® tablets in the treatment of adult patients with mild covid-19: a prospective, randomized, multicenter, open-label study |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085312/ https://www.ncbi.nlm.nih.gov/pubmed/37051002 http://dx.doi.org/10.7759/cureus.35881 |
work_keys_str_mv | AT abhyankarmahesh theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT kadamdilip theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT reddypraghavendra theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT siddiquimohammedzaki theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT ratheeshm theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT jagmagtariq theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT tilwanijayesh theefficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT abhyankarmahesh efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT kadamdilip efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT reddypraghavendra efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT siddiquimohammedzaki efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT ratheeshm efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT jagmagtariq efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy AT tilwanijayesh efficacyandsafetyofimusiltabletsinthetreatmentofadultpatientswithmildcovid19aprospectiverandomizedmulticenteropenlabelstudy |